NeuroMetrix, Inc. (NURO)

NASDAQ: NURO · IEX Real-Time Price · USD
3.50
+0.01 (0.29%)
At close: Jun 29, 2022 4:00 PM
3.44
-0.06 (-1.71%)
After-hours: Jun 29, 2022 7:14 PM EDT

Company Description

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico.

Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.

The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.

NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NeuroMetrix, Inc.
NeuroMetrix Logo
Country United States
Founded 1996
Industry Health Care Equipment & Supplies
Sector Health Care
Employees 23
CEO Shai Gozani

Contact Details

Address:
1000 Winter St
Waltham, Massachusetts 02451-1436
United States
Phone 781 890 9989
Website neurometrix.com

Stock Details

Ticker Symbol NURO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001289850
CUSIP Number 641255104
ISIN Number US6412558073
Employer ID 04-3308180
SIC Code 3841

Key Executives

Name Position
Dr. Shai N. Gozani M.D., Ph.D. Founder, Chairman, Chief Executive Officer, President and Secretary
Thomas T. Higgins Senior Vice President, Chief Financial Officer and Treasurer
Dr. Xuan Kong Ph.D. Chief Data Scientist
Susan M. Bell R.N. Senior Vice President of Population Health and Value Based Care

Latest SEC Filings

Date Type Title
May 31, 2022 SD Specialized disclosure report
May 26, 2022 4 Statement of changes in beneficial ownership of securities
May 26, 2022 4 Statement of changes in beneficial ownership of securities
May 26, 2022 4 Statement of changes in beneficial ownership of securities
May 26, 2022 4 Statement of changes in beneficial ownership of securities
May 26, 2022 4 Statement of changes in beneficial ownership of securities
May 19, 2022 S-8 Securities to be offered to employees in employee benefit plans
May 3, 2022 8-K Current report
Apr 26, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Apr 26, 2022 8-K Current report